Global Hyperimmune Globulins

Hyperimmune Globulins Comprehensive Study by Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins, Others), Application (Government Institutions, Private Sector, Others), Disease (Immunodeficiency, Autoimmune Disease, Acute Infection), Form (Powdered Form, Liquid Form) Players and Region - Global Market Outlook to 2025

Hyperimmune Globulins Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Hyperimmune Globulins Market?

Hyperimmune globulins are high in antibodies that protect against specific diseases by providing passive immunity, an immunity achieved by administration of purified antibodies that provide immediate, but short-term, protection against the disease. Hyperimmune globulins are prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Recent studies estimate that hyperimmune globulins purified from plasma taken from people who have recovered from COVID-19 enhances the immune response to the virus and block its entry into cells. The factors such as Increased Prevalence of Autoimmune Disease and Increased Number of Cancer Patients are driving the global hyperimmune globulins market. Short Term Protection Against Disease and Stringent Government Rules and Regulations may hamper market growth.

The market study is being classified by Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and Others), by Application (Government Institutions, Private Sector and Others) and major geographies with country level break-up.

CSL Behring (United States), Grifols, S.A. (Spain), Biotest (Germany), Kedrion S.p.A. (Italy), Cangene (Canada), Kamada Ltd (Israel), China National Biotec Group Company (China), Hualan Biological Engineering Inc. (China), Shanghai RAAS blood products Co., Ltd. (China) and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ADMA Biologics (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Hyperimmune Globulins market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hyperimmune Globulins market by Type, Application and Region.

On the basis of geography, the market of Hyperimmune Globulins has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • High Demand for Covid-19 Infected Patients to Enhance Immune Response
  • Increased Prevalence of Autoimmune Disease
  • Increased Number of Cancer Patients

Market Trend
  • Increased Number of Hospitals and Clinics
  • High Research and Development Investments

Restraints
  • Short Term Protection Against Disease
  • Availability of Alternative Treatments

Opportunities
  • Growing Geriatric Population Worldwide
  • Increasing Health Awareness among People
  • Current Covid-19 Panedemic around the World

Challenges
  • Stringent Government Rules and Regulations


In April 2020, Kamada Ltd. and Kedrion Biopharma, two prominent biopharmaceutical companies specialized in plasma-derived protein therapeutics,has announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARs-COV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients.


Key Target Audience
Hyperimmune Globulins Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Others
By Application
  • Government Institutions
  • Private Sector
  • Others
By Disease
  • Immunodeficiency
  • Autoimmune Disease
  • Acute Infection

By Form
  • Powdered Form
  • Liquid Form

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Demand for Covid-19 Infected Patients to Enhance Immune Response
      • 3.2.2. Increased Prevalence of Autoimmune Disease
      • 3.2.3. Increased Number of Cancer Patients
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Number of Hospitals and Clinics
      • 3.4.2. High Research and Development Investments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperimmune Globulins, by Type, Application, Disease, Form and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Hyperimmune Globulins (Value)
      • 5.2.1. Global Hyperimmune Globulins by: Type (Value)
        • 5.2.1.1. Hepatitis B Immunoglobulins
        • 5.2.1.2. Rabies Immunoglobulins
        • 5.2.1.3. Tetanus Immunoglobulins
        • 5.2.1.4. Others
      • 5.2.2. Global Hyperimmune Globulins by: Application (Value)
        • 5.2.2.1. Government Institutions
        • 5.2.2.2. Private Sector
        • 5.2.2.3. Others
      • 5.2.3. Global Hyperimmune Globulins by: Disease (Value)
        • 5.2.3.1. Immunodeficiency
        • 5.2.3.2. Autoimmune Disease
        • 5.2.3.3. Acute Infection
      • 5.2.4. Global Hyperimmune Globulins by: Form (Value)
        • 5.2.4.1. Powdered Form
        • 5.2.4.2. Liquid Form
      • 5.2.5. Global Hyperimmune Globulins Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hyperimmune Globulins (Volume)
      • 5.3.1. Global Hyperimmune Globulins by: Type (Volume)
        • 5.3.1.1. Hepatitis B Immunoglobulins
        • 5.3.1.2. Rabies Immunoglobulins
        • 5.3.1.3. Tetanus Immunoglobulins
        • 5.3.1.4. Others
      • 5.3.2. Global Hyperimmune Globulins by: Application (Volume)
        • 5.3.2.1. Government Institutions
        • 5.3.2.2. Private Sector
        • 5.3.2.3. Others
      • 5.3.3. Global Hyperimmune Globulins by: Disease (Volume)
        • 5.3.3.1. Immunodeficiency
        • 5.3.3.2. Autoimmune Disease
        • 5.3.3.3. Acute Infection
      • 5.3.4. Global Hyperimmune Globulins by: Form (Volume)
        • 5.3.4.1. Powdered Form
        • 5.3.4.2. Liquid Form
      • 5.3.5. Global Hyperimmune Globulins Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Hyperimmune Globulins (Price)
      • 5.4.1. Global Hyperimmune Globulins by: Type (Price)
  • 6. Hyperimmune Globulins: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CSL Behring (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Grifols, S.A. (Spain)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biotest (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kedrion S.p.A. (Italy)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cangene (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kamada Ltd (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. China National Biotec Group Company (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hualan Biological Engineering Inc. (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shanghai RAAS blood products Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hyperimmune Globulins Sale, by Type, Application, Disease, Form and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Hyperimmune Globulins (Value)
      • 7.2.1. Global Hyperimmune Globulins by: Type (Value)
        • 7.2.1.1. Hepatitis B Immunoglobulins
        • 7.2.1.2. Rabies Immunoglobulins
        • 7.2.1.3. Tetanus Immunoglobulins
        • 7.2.1.4. Others
      • 7.2.2. Global Hyperimmune Globulins by: Application (Value)
        • 7.2.2.1. Government Institutions
        • 7.2.2.2. Private Sector
        • 7.2.2.3. Others
      • 7.2.3. Global Hyperimmune Globulins by: Disease (Value)
        • 7.2.3.1. Immunodeficiency
        • 7.2.3.2. Autoimmune Disease
        • 7.2.3.3. Acute Infection
      • 7.2.4. Global Hyperimmune Globulins by: Form (Value)
        • 7.2.4.1. Powdered Form
        • 7.2.4.2. Liquid Form
      • 7.2.5. Global Hyperimmune Globulins Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hyperimmune Globulins (Volume)
      • 7.3.1. Global Hyperimmune Globulins by: Type (Volume)
        • 7.3.1.1. Hepatitis B Immunoglobulins
        • 7.3.1.2. Rabies Immunoglobulins
        • 7.3.1.3. Tetanus Immunoglobulins
        • 7.3.1.4. Others
      • 7.3.2. Global Hyperimmune Globulins by: Application (Volume)
        • 7.3.2.1. Government Institutions
        • 7.3.2.2. Private Sector
        • 7.3.2.3. Others
      • 7.3.3. Global Hyperimmune Globulins by: Disease (Volume)
        • 7.3.3.1. Immunodeficiency
        • 7.3.3.2. Autoimmune Disease
        • 7.3.3.3. Acute Infection
      • 7.3.4. Global Hyperimmune Globulins by: Form (Volume)
        • 7.3.4.1. Powdered Form
        • 7.3.4.2. Liquid Form
      • 7.3.5. Global Hyperimmune Globulins Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Hyperimmune Globulins (Price)
      • 7.4.1. Global Hyperimmune Globulins by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperimmune Globulins: by Type(USD Million)
  • Table 2. Hyperimmune Globulins Hepatitis B Immunoglobulins , by Region USD Million (2014-2019)
  • Table 3. Hyperimmune Globulins Rabies Immunoglobulins , by Region USD Million (2014-2019)
  • Table 4. Hyperimmune Globulins Tetanus Immunoglobulins , by Region USD Million (2014-2019)
  • Table 5. Hyperimmune Globulins Others , by Region USD Million (2014-2019)
  • Table 6. Hyperimmune Globulins: by Application(USD Million)
  • Table 7. Hyperimmune Globulins Government Institutions , by Region USD Million (2014-2019)
  • Table 8. Hyperimmune Globulins Private Sector , by Region USD Million (2014-2019)
  • Table 9. Hyperimmune Globulins Others , by Region USD Million (2014-2019)
  • Table 10. Hyperimmune Globulins: by Disease(USD Million)
  • Table 11. Hyperimmune Globulins Immunodeficiency , by Region USD Million (2014-2019)
  • Table 12. Hyperimmune Globulins Autoimmune Disease , by Region USD Million (2014-2019)
  • Table 13. Hyperimmune Globulins Acute Infection , by Region USD Million (2014-2019)
  • Table 14. Hyperimmune Globulins: by Form(USD Million)
  • Table 15. Hyperimmune Globulins Powdered Form , by Region USD Million (2014-2019)
  • Table 16. Hyperimmune Globulins Liquid Form , by Region USD Million (2014-2019)
  • Table 17. South America Hyperimmune Globulins, by Country USD Million (2014-2019)
  • Table 18. South America Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 19. South America Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 20. South America Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 21. South America Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 22. Brazil Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 23. Brazil Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 24. Brazil Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 25. Brazil Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 26. Argentina Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 27. Argentina Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 28. Argentina Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 29. Argentina Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 30. Rest of South America Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 31. Rest of South America Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 32. Rest of South America Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 33. Rest of South America Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 34. Asia Pacific Hyperimmune Globulins, by Country USD Million (2014-2019)
  • Table 35. Asia Pacific Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 36. Asia Pacific Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 37. Asia Pacific Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 38. Asia Pacific Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 39. China Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 40. China Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 41. China Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 42. China Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 43. Japan Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 44. Japan Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 45. Japan Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 46. Japan Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 47. India Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 48. India Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 49. India Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 50. India Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 51. South Korea Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 52. South Korea Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 53. South Korea Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 54. South Korea Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 55. Taiwan Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 56. Taiwan Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 57. Taiwan Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 58. Taiwan Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 59. Australia Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 60. Australia Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 61. Australia Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 62. Australia Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 67. Europe Hyperimmune Globulins, by Country USD Million (2014-2019)
  • Table 68. Europe Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 69. Europe Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 70. Europe Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 71. Europe Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 72. Germany Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 73. Germany Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 74. Germany Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 75. Germany Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 76. France Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 77. France Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 78. France Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 79. France Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 80. Italy Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 81. Italy Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 82. Italy Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 83. Italy Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 84. United Kingdom Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 85. United Kingdom Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 86. United Kingdom Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 87. United Kingdom Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 88. Netherlands Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 89. Netherlands Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 90. Netherlands Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 91. Netherlands Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 92. Rest of Europe Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 93. Rest of Europe Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 94. Rest of Europe Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 95. Rest of Europe Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 96. MEA Hyperimmune Globulins, by Country USD Million (2014-2019)
  • Table 97. MEA Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 98. MEA Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 99. MEA Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 100. MEA Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 101. Middle East Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 102. Middle East Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 103. Middle East Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 104. Middle East Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 105. Africa Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 106. Africa Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 107. Africa Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 108. Africa Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 109. North America Hyperimmune Globulins, by Country USD Million (2014-2019)
  • Table 110. North America Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 111. North America Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 112. North America Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 113. North America Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 114. United States Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 115. United States Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 116. United States Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 117. United States Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 118. Canada Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 119. Canada Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 120. Canada Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 121. Canada Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 122. Mexico Hyperimmune Globulins, by Type USD Million (2014-2019)
  • Table 123. Mexico Hyperimmune Globulins, by Application USD Million (2014-2019)
  • Table 124. Mexico Hyperimmune Globulins, by Disease USD Million (2014-2019)
  • Table 125. Mexico Hyperimmune Globulins, by Form USD Million (2014-2019)
  • Table 126. Hyperimmune Globulins Sales: by Type(K Tons)
  • Table 127. Hyperimmune Globulins Sales Hepatitis B Immunoglobulins , by Region K Tons (2014-2019)
  • Table 128. Hyperimmune Globulins Sales Rabies Immunoglobulins , by Region K Tons (2014-2019)
  • Table 129. Hyperimmune Globulins Sales Tetanus Immunoglobulins , by Region K Tons (2014-2019)
  • Table 130. Hyperimmune Globulins Sales Others , by Region K Tons (2014-2019)
  • Table 131. Hyperimmune Globulins Sales: by Application(K Tons)
  • Table 132. Hyperimmune Globulins Sales Government Institutions , by Region K Tons (2014-2019)
  • Table 133. Hyperimmune Globulins Sales Private Sector , by Region K Tons (2014-2019)
  • Table 134. Hyperimmune Globulins Sales Others , by Region K Tons (2014-2019)
  • Table 135. Hyperimmune Globulins Sales: by Disease(K Tons)
  • Table 136. Hyperimmune Globulins Sales Immunodeficiency , by Region K Tons (2014-2019)
  • Table 137. Hyperimmune Globulins Sales Autoimmune Disease , by Region K Tons (2014-2019)
  • Table 138. Hyperimmune Globulins Sales Acute Infection , by Region K Tons (2014-2019)
  • Table 139. Hyperimmune Globulins Sales: by Form(K Tons)
  • Table 140. Hyperimmune Globulins Sales Powdered Form , by Region K Tons (2014-2019)
  • Table 141. Hyperimmune Globulins Sales Liquid Form , by Region K Tons (2014-2019)
  • Table 142. South America Hyperimmune Globulins Sales, by Country K Tons (2014-2019)
  • Table 143. South America Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 144. South America Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 145. South America Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 146. South America Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 147. Brazil Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 148. Brazil Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 149. Brazil Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 150. Brazil Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 151. Argentina Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 152. Argentina Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 153. Argentina Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 154. Argentina Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 155. Rest of South America Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 156. Rest of South America Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 157. Rest of South America Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 158. Rest of South America Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 159. Asia Pacific Hyperimmune Globulins Sales, by Country K Tons (2014-2019)
  • Table 160. Asia Pacific Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 161. Asia Pacific Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 162. Asia Pacific Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 163. Asia Pacific Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 164. China Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 165. China Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 166. China Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 167. China Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 168. Japan Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 169. Japan Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 170. Japan Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 171. Japan Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 172. India Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 173. India Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 174. India Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 175. India Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 176. South Korea Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 177. South Korea Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 178. South Korea Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 179. South Korea Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 180. Taiwan Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 181. Taiwan Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 182. Taiwan Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 183. Taiwan Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 184. Australia Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 185. Australia Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 186. Australia Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 187. Australia Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 188. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 189. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 190. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 191. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 192. Europe Hyperimmune Globulins Sales, by Country K Tons (2014-2019)
  • Table 193. Europe Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 194. Europe Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 195. Europe Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 196. Europe Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 197. Germany Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 198. Germany Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 199. Germany Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 200. Germany Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 201. France Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 202. France Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 203. France Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 204. France Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 205. Italy Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 206. Italy Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 207. Italy Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 208. Italy Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 209. United Kingdom Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 210. United Kingdom Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 211. United Kingdom Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 212. United Kingdom Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 213. Netherlands Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 214. Netherlands Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 215. Netherlands Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 216. Netherlands Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 217. Rest of Europe Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 218. Rest of Europe Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 219. Rest of Europe Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 220. Rest of Europe Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 221. MEA Hyperimmune Globulins Sales, by Country K Tons (2014-2019)
  • Table 222. MEA Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 223. MEA Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 224. MEA Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 225. MEA Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 226. Middle East Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 227. Middle East Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 228. Middle East Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 229. Middle East Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 230. Africa Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 231. Africa Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 232. Africa Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 233. Africa Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 234. North America Hyperimmune Globulins Sales, by Country K Tons (2014-2019)
  • Table 235. North America Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 236. North America Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 237. North America Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 238. North America Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 239. United States Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 240. United States Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 241. United States Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 242. United States Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 243. Canada Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 244. Canada Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 245. Canada Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 246. Canada Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 247. Mexico Hyperimmune Globulins Sales, by Type K Tons (2014-2019)
  • Table 248. Mexico Hyperimmune Globulins Sales, by Application K Tons (2014-2019)
  • Table 249. Mexico Hyperimmune Globulins Sales, by Disease K Tons (2014-2019)
  • Table 250. Mexico Hyperimmune Globulins Sales, by Form K Tons (2014-2019)
  • Table 251. Hyperimmune Globulins: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Hyperimmune Globulins: by Type(USD Million)
  • Table 263. Hyperimmune Globulins Hepatitis B Immunoglobulins , by Region USD Million (2020-2025)
  • Table 264. Hyperimmune Globulins Rabies Immunoglobulins , by Region USD Million (2020-2025)
  • Table 265. Hyperimmune Globulins Tetanus Immunoglobulins , by Region USD Million (2020-2025)
  • Table 266. Hyperimmune Globulins Others , by Region USD Million (2020-2025)
  • Table 267. Hyperimmune Globulins: by Application(USD Million)
  • Table 268. Hyperimmune Globulins Government Institutions , by Region USD Million (2020-2025)
  • Table 269. Hyperimmune Globulins Private Sector , by Region USD Million (2020-2025)
  • Table 270. Hyperimmune Globulins Others , by Region USD Million (2020-2025)
  • Table 271. Hyperimmune Globulins: by Disease(USD Million)
  • Table 272. Hyperimmune Globulins Immunodeficiency , by Region USD Million (2020-2025)
  • Table 273. Hyperimmune Globulins Autoimmune Disease , by Region USD Million (2020-2025)
  • Table 274. Hyperimmune Globulins Acute Infection , by Region USD Million (2020-2025)
  • Table 275. Hyperimmune Globulins: by Form(USD Million)
  • Table 276. Hyperimmune Globulins Powdered Form , by Region USD Million (2020-2025)
  • Table 277. Hyperimmune Globulins Liquid Form , by Region USD Million (2020-2025)
  • Table 278. South America Hyperimmune Globulins, by Country USD Million (2020-2025)
  • Table 279. South America Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 280. South America Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 281. South America Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 282. South America Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 283. Brazil Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 284. Brazil Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 285. Brazil Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 286. Brazil Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 287. Argentina Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 288. Argentina Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 289. Argentina Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 290. Argentina Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 291. Rest of South America Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 292. Rest of South America Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 293. Rest of South America Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 294. Rest of South America Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 295. Asia Pacific Hyperimmune Globulins, by Country USD Million (2020-2025)
  • Table 296. Asia Pacific Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 297. Asia Pacific Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 298. Asia Pacific Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 299. Asia Pacific Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 300. China Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 301. China Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 302. China Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 303. China Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 304. Japan Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 305. Japan Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 306. Japan Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 307. Japan Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 308. India Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 309. India Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 310. India Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 311. India Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 312. South Korea Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 313. South Korea Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 314. South Korea Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 315. South Korea Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 316. Taiwan Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 317. Taiwan Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 318. Taiwan Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 319. Taiwan Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 320. Australia Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 321. Australia Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 322. Australia Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 323. Australia Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 324. Rest of Asia-Pacific Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 325. Rest of Asia-Pacific Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 326. Rest of Asia-Pacific Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 327. Rest of Asia-Pacific Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 328. Europe Hyperimmune Globulins, by Country USD Million (2020-2025)
  • Table 329. Europe Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 330. Europe Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 331. Europe Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 332. Europe Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 333. Germany Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 334. Germany Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 335. Germany Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 336. Germany Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 337. France Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 338. France Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 339. France Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 340. France Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 341. Italy Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 342. Italy Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 343. Italy Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 344. Italy Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 345. United Kingdom Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 346. United Kingdom Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 347. United Kingdom Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 348. United Kingdom Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 349. Netherlands Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 350. Netherlands Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 351. Netherlands Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 352. Netherlands Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 353. Rest of Europe Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 354. Rest of Europe Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 355. Rest of Europe Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 356. Rest of Europe Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 357. MEA Hyperimmune Globulins, by Country USD Million (2020-2025)
  • Table 358. MEA Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 359. MEA Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 360. MEA Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 361. MEA Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 362. Middle East Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 363. Middle East Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 364. Middle East Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 365. Middle East Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 366. Africa Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 367. Africa Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 368. Africa Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 369. Africa Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 370. North America Hyperimmune Globulins, by Country USD Million (2020-2025)
  • Table 371. North America Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 372. North America Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 373. North America Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 374. North America Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 375. United States Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 376. United States Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 377. United States Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 378. United States Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 379. Canada Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 380. Canada Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 381. Canada Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 382. Canada Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 383. Mexico Hyperimmune Globulins, by Type USD Million (2020-2025)
  • Table 384. Mexico Hyperimmune Globulins, by Application USD Million (2020-2025)
  • Table 385. Mexico Hyperimmune Globulins, by Disease USD Million (2020-2025)
  • Table 386. Mexico Hyperimmune Globulins, by Form USD Million (2020-2025)
  • Table 387. Hyperimmune Globulins Sales: by Type(K Tons)
  • Table 388. Hyperimmune Globulins Sales Hepatitis B Immunoglobulins , by Region K Tons (2020-2025)
  • Table 389. Hyperimmune Globulins Sales Rabies Immunoglobulins , by Region K Tons (2020-2025)
  • Table 390. Hyperimmune Globulins Sales Tetanus Immunoglobulins , by Region K Tons (2020-2025)
  • Table 391. Hyperimmune Globulins Sales Others , by Region K Tons (2020-2025)
  • Table 392. Hyperimmune Globulins Sales: by Application(K Tons)
  • Table 393. Hyperimmune Globulins Sales Government Institutions , by Region K Tons (2020-2025)
  • Table 394. Hyperimmune Globulins Sales Private Sector , by Region K Tons (2020-2025)
  • Table 395. Hyperimmune Globulins Sales Others , by Region K Tons (2020-2025)
  • Table 396. Hyperimmune Globulins Sales: by Disease(K Tons)
  • Table 397. Hyperimmune Globulins Sales Immunodeficiency , by Region K Tons (2020-2025)
  • Table 398. Hyperimmune Globulins Sales Autoimmune Disease , by Region K Tons (2020-2025)
  • Table 399. Hyperimmune Globulins Sales Acute Infection , by Region K Tons (2020-2025)
  • Table 400. Hyperimmune Globulins Sales: by Form(K Tons)
  • Table 401. Hyperimmune Globulins Sales Powdered Form , by Region K Tons (2020-2025)
  • Table 402. Hyperimmune Globulins Sales Liquid Form , by Region K Tons (2020-2025)
  • Table 403. South America Hyperimmune Globulins Sales, by Country K Tons (2020-2025)
  • Table 404. South America Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 405. South America Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 406. South America Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 407. South America Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 408. Brazil Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 409. Brazil Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 410. Brazil Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 411. Brazil Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 412. Argentina Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 413. Argentina Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 414. Argentina Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 415. Argentina Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 416. Rest of South America Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 417. Rest of South America Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 418. Rest of South America Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 419. Rest of South America Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 420. Asia Pacific Hyperimmune Globulins Sales, by Country K Tons (2020-2025)
  • Table 421. Asia Pacific Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 422. Asia Pacific Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 423. Asia Pacific Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 424. Asia Pacific Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 425. China Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 426. China Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 427. China Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 428. China Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 429. Japan Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 430. Japan Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 431. Japan Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 432. Japan Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 433. India Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 434. India Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 435. India Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 436. India Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 437. South Korea Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 438. South Korea Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 439. South Korea Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 440. South Korea Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 441. Taiwan Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 442. Taiwan Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 443. Taiwan Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 444. Taiwan Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 445. Australia Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 446. Australia Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 447. Australia Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 448. Australia Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 449. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 450. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 451. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 452. Rest of Asia-Pacific Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 453. Europe Hyperimmune Globulins Sales, by Country K Tons (2020-2025)
  • Table 454. Europe Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 455. Europe Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 456. Europe Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 457. Europe Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 458. Germany Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 459. Germany Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 460. Germany Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 461. Germany Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 462. France Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 463. France Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 464. France Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 465. France Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 466. Italy Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 467. Italy Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 468. Italy Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 469. Italy Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 470. United Kingdom Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 471. United Kingdom Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 472. United Kingdom Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 473. United Kingdom Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 474. Netherlands Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 475. Netherlands Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 476. Netherlands Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 477. Netherlands Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 478. Rest of Europe Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 479. Rest of Europe Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 480. Rest of Europe Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 481. Rest of Europe Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 482. MEA Hyperimmune Globulins Sales, by Country K Tons (2020-2025)
  • Table 483. MEA Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 484. MEA Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 485. MEA Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 486. MEA Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 487. Middle East Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 488. Middle East Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 489. Middle East Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 490. Middle East Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 491. Africa Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 492. Africa Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 493. Africa Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 494. Africa Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 495. North America Hyperimmune Globulins Sales, by Country K Tons (2020-2025)
  • Table 496. North America Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 497. North America Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 498. North America Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 499. North America Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 500. United States Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 501. United States Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 502. United States Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 503. United States Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 504. Canada Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 505. Canada Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 506. Canada Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 507. Canada Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 508. Mexico Hyperimmune Globulins Sales, by Type K Tons (2020-2025)
  • Table 509. Mexico Hyperimmune Globulins Sales, by Application K Tons (2020-2025)
  • Table 510. Mexico Hyperimmune Globulins Sales, by Disease K Tons (2020-2025)
  • Table 511. Mexico Hyperimmune Globulins Sales, by Form K Tons (2020-2025)
  • Table 512. Hyperimmune Globulins: by Type(USD/Units)
  • Table 513. Research Programs/Design for This Report
  • Table 514. Key Data Information from Secondary Sources
  • Table 515. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperimmune Globulins: by Type USD Million (2014-2019)
  • Figure 5. Global Hyperimmune Globulins: by Application USD Million (2014-2019)
  • Figure 6. Global Hyperimmune Globulins: by Disease USD Million (2014-2019)
  • Figure 7. Global Hyperimmune Globulins: by Form USD Million (2014-2019)
  • Figure 8. South America Hyperimmune Globulins Share (%), by Country
  • Figure 9. Asia Pacific Hyperimmune Globulins Share (%), by Country
  • Figure 10. Europe Hyperimmune Globulins Share (%), by Country
  • Figure 11. MEA Hyperimmune Globulins Share (%), by Country
  • Figure 12. North America Hyperimmune Globulins Share (%), by Country
  • Figure 13. Global Hyperimmune Globulins: by Type K Tons (2014-2019)
  • Figure 14. Global Hyperimmune Globulins: by Application K Tons (2014-2019)
  • Figure 15. Global Hyperimmune Globulins: by Disease K Tons (2014-2019)
  • Figure 16. Global Hyperimmune Globulins: by Form K Tons (2014-2019)
  • Figure 17. South America Hyperimmune Globulins Share (%), by Country
  • Figure 18. Asia Pacific Hyperimmune Globulins Share (%), by Country
  • Figure 19. Europe Hyperimmune Globulins Share (%), by Country
  • Figure 20. MEA Hyperimmune Globulins Share (%), by Country
  • Figure 21. North America Hyperimmune Globulins Share (%), by Country
  • Figure 22. Global Hyperimmune Globulins: by Type USD/Units (2014-2019)
  • Figure 23. Global Hyperimmune Globulins share by Players 2019 (%)
  • Figure 24. Global Hyperimmune Globulins share by Players (Top 3) 2019(%)
  • Figure 25. Global Hyperimmune Globulins share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 28. CSL Behring (United States) Revenue: by Geography 2019
  • Figure 29. Grifols, S.A. (Spain) Revenue, Net Income and Gross profit
  • Figure 30. Grifols, S.A. (Spain) Revenue: by Geography 2019
  • Figure 31. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Biotest (Germany) Revenue: by Geography 2019
  • Figure 33. Kedrion S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 34. Kedrion S.p.A. (Italy) Revenue: by Geography 2019
  • Figure 35. Cangene (Canada) Revenue, Net Income and Gross profit
  • Figure 36. Cangene (Canada) Revenue: by Geography 2019
  • Figure 37. Kamada Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 38. Kamada Ltd (Israel) Revenue: by Geography 2019
  • Figure 39. China National Biotec Group Company (China) Revenue, Net Income and Gross profit
  • Figure 40. China National Biotec Group Company (China) Revenue: by Geography 2019
  • Figure 41. Hualan Biological Engineering Inc. (China) Revenue, Net Income and Gross profit
  • Figure 42. Hualan Biological Engineering Inc. (China) Revenue: by Geography 2019
  • Figure 43. Shanghai RAAS blood products Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 44. Shanghai RAAS blood products Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 45. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 46. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 47. Global Hyperimmune Globulins: by Type USD Million (2020-2025)
  • Figure 48. Global Hyperimmune Globulins: by Application USD Million (2020-2025)
  • Figure 49. Global Hyperimmune Globulins: by Disease USD Million (2020-2025)
  • Figure 50. Global Hyperimmune Globulins: by Form USD Million (2020-2025)
  • Figure 51. South America Hyperimmune Globulins Share (%), by Country
  • Figure 52. Asia Pacific Hyperimmune Globulins Share (%), by Country
  • Figure 53. Europe Hyperimmune Globulins Share (%), by Country
  • Figure 54. MEA Hyperimmune Globulins Share (%), by Country
  • Figure 55. North America Hyperimmune Globulins Share (%), by Country
  • Figure 56. Global Hyperimmune Globulins: by Type K Tons (2020-2025)
  • Figure 57. Global Hyperimmune Globulins: by Application K Tons (2020-2025)
  • Figure 58. Global Hyperimmune Globulins: by Disease K Tons (2020-2025)
  • Figure 59. Global Hyperimmune Globulins: by Form K Tons (2020-2025)
  • Figure 60. South America Hyperimmune Globulins Share (%), by Country
  • Figure 61. Asia Pacific Hyperimmune Globulins Share (%), by Country
  • Figure 62. Europe Hyperimmune Globulins Share (%), by Country
  • Figure 63. MEA Hyperimmune Globulins Share (%), by Country
  • Figure 64. North America Hyperimmune Globulins Share (%), by Country
  • Figure 65. Global Hyperimmune Globulins: by Type USD/Units (2020-2025)
List of companies from research coverage that are profiled in the study
  • CSL Behring (United States)
  • Grifols, S.A. (Spain)
  • Biotest (Germany)
  • Kedrion S.p.A. (Italy)
  • Cangene (Canada)
  • Kamada Ltd (Israel)
  • China National Biotec Group Company (China)
  • Hualan Biological Engineering Inc. (China)
  • Shanghai RAAS blood products Co., Ltd. (China)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
Additional players considered in the study are as follows:
ADMA Biologics (United States)
Select User Access Type

Key Highlights of Report


Nov 2020 203 Pages 77 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hyperimmune Globulins Quantitative research analysis
Global Hyperimmune Globulins Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Hyperimmune Globulins Report?

Have a Query? Click Here

Other Related Reports

Immunoglobulin Products Comprehensive Study by Type (IgA, IgG, IgM, IgD, IgE), Application (Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hypogammaglobulinemia, Immunode...
$ 3750
Hyperphosphatemia Drugs Comprehensive Study by Type (Aluminum Phosphate Binder, Iron Phosphate Binder, Magnesium Phosphate Binder, Calcium Phosphate Binder), Application (Hospitals, Clinics, Others),...
$ 3650
Cancer CDK Inhibitors Comprehensive Study by Type (Ibrance (palbociclib), Kisqali (ribociclib), Verzenio (abemaciclib)), Application (Hospitals, Clinics, Other), Distribution Channel (Hospital Pharma...
$ 3350
Human Chorionic Gonadotropin Comprehensive Study by Technology (Natural Source Extraction, Recombinant Technology), End User (Fertility Clinics, Research Institutions, Others), Therapeutic Area (Fema...
$ 3450
Hib Vaccine Comprehensive Study by Type (Type 1-HIB Vaccine, Type 2- DTaP-IPV), Form (Liquid Monovalent HIB, Liquid Combination HIB, Lyophilized Monovalent HIB, Lyophilized Combination HIB), Age Grou...
$ 3750
Breast Cancer Predictive Genetic Testing Comprehensive Study by Type (High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes), Application (Hospitals, Clinic Center, Pharmaceuticals,...
$ 3500